DEA Rescheduled Marijuana: Key Regulatory Update March 2026
The DEA rescheduled marijuana from Schedule I to Schedule III, recognizing its medical utility. This regulatory update impacts prescribing restrictions for healthcare providers. The dea rescheduled marijuana change is a significant development in…
DEA Scheduling Synthetic Opioids 2026 Regulatory Updates
This update covers DEA scheduling synthetic opioids 2026 regulatory actions affecting controlled substances. These changes influence clinical practices involving controlled drugs. Cannabis medicine remains primarily governed by state laws and federal…
Cannabis Medicine Regulations 2026: Key Updates March 13
This update covers cannabis medicine regulations 2026, highlighting key controlled substances scheduling and Medicare policy changes. These regulatory updates impact clinical research and patient access. Cannabis clinicians should stay informed on…
DEA Scheduling Synthetic Cannabinoids: March 2026 Updates
This update covers DEA scheduling synthetic cannabinoids and other controlled substances relevant to cannabis clinicians. Medicare and Medicaid policy changes also affect cannabis treatment reimbursement. These regulatory updates shape the clinical…
